Pravin T Kaumaya PhD

Pravin T Kaumaya PhD
ProfessorCollege of Medicinekaumaya.1@osu.edu
316 Tzagournis Med Res Facility 420 W 12th Avenue Columbus Ohio 43210
Phone:614-292-7028Alternate Phone:614-292-0726Fax: 614-292-1135
  • Translational Therapeutics

Research Description

Dr. Kaumaya investigates how patients’ immune systems can be directed to recognize and kill their own cancer cells

Current Publications

  • Kaumaya PTBridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics.Immunotherapy 5 1159-63 11/1/2013
  • Foy KC, Wygle RM, Miller MJ, Overholser JP, Bekaii-Saab T, Kaumaya PTPeptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.J Immunol 191 217-27 7/1/2013
  • Miller MJ, Foy KC, Kaumaya PTCancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics.Discov Med 15 166-76 3/1/2013
  • Foy KC, Miller MJ, Moldovan N, Bozanovic T, Carson Iii WE, Kaumaya PTImmunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer.Oncoimmunology 1 1004-1016 10/1/2012
  • Foy KC, Miller MJ, Moldovan N, Carson Iii WE, Kaumaya PTCombined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.Oncoimmunology 1 1048-1060 10/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu